Back to News
Market Impact: 0.35
Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad
Source: PR Newswire
Healthcare & Biotech
Sobi reported that detailed results from a pivotal Phase 3 study of investigational once-daily URAT1 inhibitor pozdeutinurad showed statistically significant serum urate reductions through 12 months. The announcement also included safety results, but the provided article text gives no numerical efficacy or safety details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SOBI0.65
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Aspen Neuroscience prices IPO at $15 per share
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq